Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data
Key Takeaways Raymond James analysts upgraded Gilead Sciences stock to "outperform" from "market perform." The upgrade was driven by Gilead's drug lenacapavir, which showed a 100% effectiveness rate in preventing HIV infection in …